Filing Details
- Accession Number:
- 0001209191-15-005340
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-01-20 21:18:07
- Reporting Period:
- 2015-01-16
- Filing Date:
- 2015-01-20
- Accepted Time:
- 2015-01-20 21:18:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1466301 | Clovis Oncology Inc. | CLVS | Pharmaceutical Preparations (2834) | 900475355 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1533451 | L. Steven Hoerter | C/O Clovis Oncology, Inc. 2525 28Th Street, Suite 100 Boulder CO 80301 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-01-16 | 10,000 | $11.02 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-01-16 | 10,000 | $67.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2015-01-16 | 10,000 | $0.00 | 10,000 | $11.02 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
56,206 | 2021-08-29 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.
- The option is immediately exercisable as to both vested and unvested shares. The option vested as to 25% of the shares on August 29, 2012 and the remainder have and will continue to vest in substantially equal installments over the 36 months immediately following such date. To the extent the reporting person exercises the option as to unvested shares, the reporting person will receive restricted shares that will vest in accordance with the vesting schedule for the option.